DEC 29, 2016 8:02 AM PST

Positive Results for Ocrelizumab Raise Hope for MS Cure

WRITTEN BY: Xuan Pham

A drug that weakens the immune system is showing big promise as potentially the first treatment option for multiple sclerosis (MS). In three large-scale, multi-center clinical trials, the drug ocrelizumab was shown to be effective against both types of multiple sclerosis, the progressive form and the relapsing remitting form.

"It's very significant because this is the first time a phase three trial has been positive in primary progressive MS,” said Gavin Giovannoni, professor at the Barts and The London School of Medicine and Dentistry, and co-author of the study, published in the New England Journal of Medicine.

Multiple sclerosis is described as a demyelinating disease whereby the body’s immune system mistakenly attacks the myelin sheath covers in the brain and spinal cord. This disrupts the electrical signal traveling from the brain to the body, and leads to physical and neurologic disabilities. The progressive form of MS causes patients to slowly deteriorate over time, while the relapsing form causes patients to go through bouts of symptoms and recovery. There is no cure for either form of MS.

To combat a rogue immune system, researchers focused on a drug that can quell the assault on the myelin sheath. Indeed, ocrelizumab, patented by Hoffman-La Roche, prevents the B cells from attacking the protective myelin covers. 

Tested in patients with both forms of MS, the drug seems to stop the inflammation process in the brain. This results in less fatigue and muscle weakness. Vision seems to also be improved. Furthermore, scans show significantly less brain loss with the help of ocrelizumab.

"The results shown by these studies have the potential to change how we approach treating both relapsing and primary progressive MS,” said Giovannoni.

The drug is under evaluation from both the European Medicines Agency and the U.S. FDA.

Despite the big promises for MS, researchers are cautiously optimistic as a drug that dampens the immune system could incur other health troubles, such as infection and cancer. As such, they are rigorously testing for side effects associated with the drug.

"This is the first drug to show a significant effect in slowing disability progression in a phase three trial in primary progressive multiple sclerosis and therefore represents a landmark study in the field,” said Peter Calabresi, professor of Neurology from Johns Hopkins University who was not associated with the study.

Additional sources: BBC

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 07, 2022
Cardiology
Reduce TV Viewing to Prevent Heart Disease
JUL 07, 2022
Reduce TV Viewing to Prevent Heart Disease
According to new research, over 10% of coronary heart disease cases could be prevented by watching less than one hour of ...
JUL 14, 2022
Cardiology
Air Pollution Linked to Heart Arrhythmia
JUL 14, 2022
Air Pollution Linked to Heart Arrhythmia
Dangerous arrhythmias are more common on high-pollution days.
JUL 13, 2022
Clinical & Molecular DX
Nipah Virus: Moderna Invests in a Vaccine for the Virus that Fauci Calls a 'Pandemic Threat'
JUL 13, 2022
Nipah Virus: Moderna Invests in a Vaccine for the Virus that Fauci Calls a 'Pandemic Threat'
In Malaysia in the fall of 1998, a mystery ailment swept through the local pig-farming community, eventually leading to ...
AUG 04, 2022
Clinical & Molecular DX
Artificial Intelligence Shows Promise in Diagnosing Strokes
AUG 04, 2022
Artificial Intelligence Shows Promise in Diagnosing Strokes
Quick identification and intervention is critical in successfully treating a stroke. During a stroke, blood supply to th ...
AUG 10, 2022
Health & Medicine
Newly ID'ed Langya Virus Sickens Dozens in China
AUG 10, 2022
Newly ID'ed Langya Virus Sickens Dozens in China
Zoonotic diseases, which can jump from one species to another, are not unusual. As the world's population rises and the ...
AUG 16, 2022
Neuroscience
A Common Denominator Among All Forms of ALS is Revealed
AUG 16, 2022
A Common Denominator Among All Forms of ALS is Revealed
ALS (amyotrophic lateral sclerosis) is a motor neuron disease, which gradually causes a loss of movement. Eventually, pa ...
Loading Comments...